Financial Performance - The company's operating revenue for Q3 2024 was CNY 1,620,477,351.66, representing a year-on-year increase of 6.71%[3] - The net profit attributable to shareholders decreased by 25.97% year-on-year, totaling CNY 221,561,280.86[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 27.69%, amounting to CNY 227,362,356.93[3] - Basic earnings per share for the current period decreased by 33.33% to CNY 0.17[3] - The company reported a 44.31% decrease in net profit attributable to shareholders for the year-to-date period[6] - Total operating revenue for the first three quarters of 2024 reached ¥4,871,569,389.30, an increase of 2.4% compared to ¥4,756,623,138.17 in the same period of 2023[14] - Net profit for the first three quarters of 2024 was ¥314,944,634.66, a decrease of 37.1% from ¥500,719,228.70 in the same period of 2023[17] - Operating profit for the first three quarters of 2024 was ¥492,182,584.08, down 26.0% from ¥665,562,779.52 in 2023[16] - The total comprehensive income for the first three quarters of 2024 was ¥213,465,308.78, significantly lower than ¥690,450,986.38 in 2023[17] Assets and Liabilities - Total assets at the end of the reporting period were CNY 25,776,697,287.81, a slight increase of 0.22% compared to the beginning of the year[3] - As of September 30, 2024, the company's total assets amounted to RMB 25,776,697,287.81, a slight increase from RMB 25,719,533,432.05 at the end of 2023[11] - The company's total current liabilities decreased slightly to RMB 5,929,892,848.55 from RMB 5,966,368,169.54, a reduction of approximately 0.6%[12] - Total liabilities decreased to ¥6,913,246,838.78 from ¥7,017,213,664.98, indicating a reduction of approximately 1.5%[13] - Non-current assets totaled RMB 16,977,286,399.61, down from RMB 17,193,219,839.43, representing a decrease of about 1.3%[12] Shareholder Information - The equity attributable to shareholders increased by 0.33% to CNY 17,374,441,925.95[3] - The number of ordinary shareholders at the end of the reporting period was 42,781[7] - The largest shareholder, Sanpower Group Co., Ltd., holds 35.99% of the shares, with a total of 484,482,721 shares[7] - Total equity attributable to shareholders increased to ¥17,374,441,925.95 from ¥17,316,561,908.02, reflecting a growth of 0.3%[13] Cash Flow - The company's cash and cash equivalents decreased to RMB 4,604,397,543.23 from RMB 5,000,758,404.36, representing a decline of approximately 7.9%[11] - In the first three quarters of 2024, the company reported cash inflows from operating activities totaling ¥6,322,365,811.40, a decrease of approximately 4.25% compared to ¥6,603,735,229.30 in the same period of 2023[18] - The net cash flow from operating activities for the first three quarters of 2024 was ¥547,541,438.45, slightly down from ¥558,476,612.23 in 2023, indicating a decrease of about 1.68%[18] - Cash inflows from investment activities amounted to ¥608,748,820.85, while cash outflows totaled ¥1,405,482,672.16, resulting in a net cash flow from investment activities of -¥796,733,851.31, compared to -¥948,160,870.39 in 2023[19] - The total cash outflow from financing activities was ¥381,519,038.81, down from ¥492,948,365.97 in the previous year, reflecting a decrease of approximately 22.6%[19] - The company received cash from financing activities totaling ¥281,731,173.84, a significant decrease from ¥548,404,248.84 in the same period last year, indicating a decline of about 48.7%[19] Expenses - Total operating costs for the first three quarters of 2024 were ¥4,373,402,633.27, up from ¥4,117,070,060.96 in 2023, reflecting a year-on-year increase of 6.3%[16] - Research and development expenses for the first three quarters of 2024 amounted to ¥172,485,324.04, a decrease of 13.8% compared to ¥200,084,818.54 in 2023[16] - The company's cash outflow for purchasing goods and services was ¥2,420,825,999.63, down from ¥2,675,031,475.65 in the previous year, reflecting a decrease of about 9.5%[18] Non-Recurring Items - Non-recurring gains and losses for the current period totaled CNY 6,708,803.66, with a significant impact from government subsidies and asset disposals[5] - The company's goodwill stood at RMB 6,017,392,806.77, a minor decrease from RMB 6,048,553,377.12, reflecting a decline of approximately 0.5%[12] - The company’s deferred income tax liabilities decreased to ¥357,126,636.93 from ¥366,619,245.98, showing a decline of about 2.0%[13]

证券代码：600682 证券简称：南京新百 公告编号：临 2024-027 南京新街口百货商店股份有限公司 2024年半年度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）根据上海证券交易所《上市公 司自律监管指引第 3 号——行业信息披露》之《第四号——零售》的相关要求，现将 公司 2024 年半年度主要经营数据（未经审计）公告如下： 一、2024 年半年度主要经营数据如下： （一）主营业务分行业情况 （二）主营业务分地区情况 公告编号: 临 2024-027 | स्त्री | 10, 647, 990. 88 | 10, 956, 228. 21 | -2. 89 | -20. 96 | 20. 52 | -35.42 | | --- | --- | --- | --- | --- | --- | --- | | 华南 | 62, 176, 672. 44 | 53, 385, 907. 06 | 14.14 | 371. 15 | 313. 89 | 11. ...

Financial Performance - Revenue for the first half of 2024 was RMB 3,251,092,037.64, a slight increase of 0.40% compared to the same period last year[14] - Net profit attributable to shareholders of the company was RMB 165,216,088.95, a significant decrease of 48.65% year-on-year[14] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 177,725,968.69, down 41.86% compared to the same period last year[15] - Net cash flow from operating activities was RMB 277,805,739.78, a decrease of 32.93% year-on-year[15] - Basic earnings per share decreased by 50% to 0.12 yuan from 0.24 yuan in the same period last year[16] - Diluted earnings per share also decreased by 50% to 0.12 yuan from 0.24 yuan in the same period last year[16] - Weighted average return on equity decreased by 0.91 percentage points to 0.95% from 1.86% in the same period last year[16] - Non-recurring gains and losses included government subsidies of 1,297,666.67 yuan and gains from financial assets and liabilities of 9,136,567.12 yuan[16] - Total revenue for the first half of 2024 reached RMB 3,251,092,037.64, a slight increase from RMB 3,237,999,385.85 in the same period of 2023[140] - Net profit for the first half of 2024 was RMB 234,803,490.44, a decrease from RMB 400,334,851.63 in the same period of 2023[141] - Operating profit for the first half of 2024 was RMB 368,012,014.56, a decrease from RMB 531,982,577.40 in the same period of 2023[141] - Research and development expenses for the first half of 2024 were RMB 116,141,878.23, slightly down from RMB 119,714,256.18 in the same period of 2023[140] - Total operating costs for the first half of 2024 were RMB 2,869,991,133.84, up from RMB 2,725,070,370.50 in the same period of 2023[140] - Revenue for the first half of 2024 was RMB 264.23 million, compared to RMB 288.32 million in the same period of 2023[143] - Operating profit for the first half of 2024 was a loss of RMB 47.49 million, compared to a loss of RMB 13.53 million in the same period of 2023[145] - Net profit for the first half of 2024 was a loss of RMB 61.09 million, compared to a loss of RMB 11.22 million in the same period of 2023[145] - Basic earnings per share for the first half of 2024 were RMB -0.05, compared to RMB -0.01 in the same period of 2023[145] - Total comprehensive income for the first half of 2024 was RMB -61.02 million, compared to RMB -10.55 million in the same period of 2023[145] - Cash flow from operating activities for the first half of 2024 was RMB 277.81 million, compared to RMB 414.22 million in the same period of 2023[146] - Sales revenue from goods and services for the first half of 2024 was RMB 3.92 billion, compared to RMB 4.20 billion in the same period of 2023[146] - Cash paid for goods and services in the first half of 2024 was RMB 1.66 billion, compared to RMB 1.82 billion in the same period of 2023[146] - Cash paid to employees in the first half of 2024 was RMB 1.39 billion, compared to RMB 1.37 billion in the same period of 2023[146] - Cash paid for taxes in the first half of 2024 was RMB 207.94 million, compared to RMB 200.18 million in the same period of 2023[146] - Investment cash outflow totaled 1,031,745,814.57 yuan, a decrease of 20.4% compared to the previous period[147] - Net cash flow from investment activities was -689,417,972.49 yuan, a significant decline from -255,934,712.47 yuan in the previous period[147] - Net cash flow from financing activities was -25,039,146.40 yuan, compared to 31,593,838.43 yuan in the previous period[147] - Cash and cash equivalents at the end of the period were 4,512,798,517.10 yuan, a decrease of 12.0% from the previous period[147] - Operating cash inflow was 830,255,185.31 yuan, a decrease of 14.7% compared to the previous period[148] - Net cash flow from operating activities was -33,412,555.44 yuan, slightly worse than -31,933,786.37 yuan in the previous period[148] - Investment cash inflow was 32,402,250.00 yuan, a significant increase from 3,198,857.34 yuan in the previous period[149] - Net cash flow from investment activities was 22,353,170.31 yuan, a decrease of 44.8% compared to the previous period[149] - Net cash flow from financing activities was 37,916,946.54 yuan, a decrease of 19.6% compared to the previous period[149] - Cash and cash equivalents at the end of the period were 165,280,806.73 yuan, a decrease of 46.0% from the previous period[149] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 26,020,091,860.95, an increase of 1.17% compared to the end of the previous year[15] - The asset-liability ratio remained stable at 27.28%, showing no significant change[15] - Total assets as of the end of the first half of 2024 amounted to RMB 17,303,724,500.92, showing minimal change from RMB 17,293,824,254.85 at the end of the same period in 2023[138] - Total liabilities for the first half of 2024 were RMB 5,325,016,956.91, up from RMB 5,213,919,609.48 in the same period of 2023[139] - Long-term equity investments as of the end of the first half of 2024 stood at RMB 11,964,840,834.38, showing a slight decrease from RMB 11,978,165,636.71 at the end of the same period in 2023[138] - Total equity attributable to shareholders as of the end of the first half of 2024 was RMB 11,978,707,544.01, down from RMB 12,079,904,645.37 at the end of the same period in 2023[139] - Interest income for the first half of 2024 was RMB -80,742,669.62, compared to RMB -68,785,546.39 in the same period of 2023[141] - Total assets increased to 26,020,091,860.95 RMB, up from 25,719,533,432.05 RMB at the end of 2023[134][136] - Cash and cash equivalents decreased to 4,571,368,460.76 RMB from 5,000,758,404.36 RMB at the end of 2023[134] - Trade receivables increased to 1,444,731,695.63 RMB, up from 1,347,231,606.81 RMB at the end of 2023[134] - Inventory rose to 516,869,668.48 RMB, compared to 456,718,566.56 RMB at the end of 2023[134] - Total liabilities increased to 7,097,829,469.68 RMB, up from 7,017,213,664.98 RMB at the end of 2023[135][136] - Contract liabilities increased to 3,376,072,068.37 RMB, up from 3,298,076,377.01 RMB at the end of 2023[135] - Total equity increased to 18,922,262,391.27 RMB, up from 18,702,319,767.07 RMB at the end of 2023[136] - Development expenditure increased to 257,753,949.49 RMB, up from 229,987,339.85 RMB at the end of 2023[135] - Short-term borrowings increased to 551,458,997.22 RMB, up from 530,471,645.83 RMB at the end of 2023[135] - Other receivables in the parent company increased to 2,690,810,835.69 RMB, up from 2,550,304,841.54 RMB at the end of 2023[137] - Overseas assets amounted to 9.836 billion RMB, accounting for 37.80% of total assets[56] - Restricted assets totaled 1.35 billion RMB, including mortgage loans for properties such as the Xuzhou New Health Hospital outpatient building[58][59][60] - Long-term equity investments decreased by 13.32 million RMB to 425.91 million RMB due to equity method accounting for joint ventures[61] - Other equity instrument investments increased by 31 million RMB to 1.531 billion RMB, driven by new investments of 30 million RMB[61] - Securities investments totaled 510.03 million RMB, including stocks like Ninghu Expressway and Nanjing Securities[62] - The company invested 10,000 million RMB in Shanghai Xunchuang Investment Management Center, with 5,000 million RMB already transferred[63] - The company invested 40,000 million RMB in Nanjing Yingpeng Huikang Medical Industry Investment Partnership, with full payment completed[63] - The company's subsidiary invested 62,930 million RMB in Xinlu Dazeshengke (Hainan) Private Equity Fund Partnership, with 46,900 million RMB already paid[64] Subsidiaries and Business Operations - The company has subsidiaries such as Ankangtong, Hekang, and Dendreon, which are involved in healthcare and biotechnology sectors[6] - Ankang Tong has covered over 20 million elderly users and provided 200 million home care services[19] - Hekang serves over 12 million elderly users annually across more than 234 districts in over 10 provinces[21] - Natali successfully acquired UK home care service companies Nobilis and Horizon, expanding into the UK market[21] - A.S. Nursing provides home care services primarily to elderly individuals over 75 years old, disabled veterans, and other disabled persons, with services billed based on care hours by the Israeli National Insurance Institute[22] - Natali (China) focuses on two main business lines: family health management services and integrated health and elderly care services, aiming to become a data-driven, user-centric high-end health management service provider[23] - Shandong Qilu Stem Cell Engineering Co., Ltd. specializes in umbilical cord blood stem cell testing, preparation, storage, and provision, serving pregnant women and hospitals[24] - Dendreon US, a subsidiary of Shidai Hong Kong, focuses on the development, production, and sales of tumor cell immunotherapy products, with its flagship product PROVENGE approved by the FDA in 2010[25] - PROVENGE has been used in over 40,000 patients in the US, capturing 10% of the prostate cancer treatment market, and is currently undergoing Phase III clinical trials in China with 108 out of 140 planned patients enrolled[25] - Nanjing Dendreon's main asset, Dendreon China, is advancing the clinical development of PROVENGE in China, with positive efficacy and safety results observed in ongoing trials[25] - The company operates one of the 7 approved cord blood banks in China, located in Shandong province[27] - The hospital provides specialized medical services across 14 departments, including cardiology, neurology, and oncology[27] - The hospital conducts clinical education for Xuzhou Medical University and provides technical guidance to lower-tier medical institutions[27] - The company's health and elderly care business, Ankangtong, has developed a comprehensive elderly care service system with over 100 software copyrights and a standardized operational framework[34] - Ankangtong has established a big data ecosystem for elderly care, enabling service process supervision, dynamic quality analysis, and user assessment[34] - Hekang, another elderly care service provider, serves nearly 4 million elderly across 10 provinces and over 200 districts, offering a full range of care services[34] - Hekang has developed a smart elderly care big data system, enabling service capability sharing and development of smart nursing homes, medical services, and communities[34] - Natali, a global elderly care service provider, has a unique business model integrating remote medical and care services, with a strong focus on the 73-75+ age group[35] - Natali's business model is highly replicable, with 30+ years of operational experience enabling rapid international expansion[35] - Natali and A.S. Nursing have established vertical synergy, with Natali's emergency and remote medical services identifying potential users for A.S. Nursing's home care services[35] - Natali (China) has optimized its home care products to include the most efficient home monitoring modes, such as 24-hour dynamic ECG and blood pressure monitoring, significantly reducing hardware procurement and service operation costs[36] - Natali (China) leverages the synergy with Ankangtong, which provides target user data and a mature offline service team to support the implementation of high-end customized home care services[36] - Qilu Stem Cell has a large customer base with nearly 20 years of development, providing a rich cell resource foundation for diversified products and services[36] - Qilu Stem Cell has established a comprehensive service network, covering secondary and above hospitals in Shandong Province and collaborating with hospitals in over 20 provinces across China[37] - Qilu Stem Cell has a robust operational management system, including a real-time tracking mechanism for departmental plans and a two-way communication system to ensure strategic implementation[38] - Dendreon US has over 20 years of R&D experience in cell immunotherapy for mCRPC patients, with a mature production process and FDA-certified treatment protocols[39] - Dendreon China is actively expanding its industrial layout, planning to build a GMP-compliant commercial cell factory to meet future production needs for PROVENGE® and other cell products[40] - New Health Hospital has introduced high-quality medical resources and established a comprehensive cooperation model with Jiangsu Provincial People's Hospital, including expert workstations and specialized outpatient services[40] - Ankangtong successfully bid for 82 projects and expanded to 3 new cities: Yinchuan, Yuncheng, and Huzhou[43] - Ankangtong's smart product library includes approximately 100 smart products across 9 categories and 200 non-smart products across 8 categories[43] - Ankangtong won the "2024 Digital Intelligence Elderly Care Benchmark Enterprise" award[44] - Natali's cumulative revenue increased by 10.7% year-on-year, with nursing business and private payment business revenues growing by 9.6% and 13.6% respectively[45] - Natali added over 800 core private payment users and sold more than 1,400 smart wearable devices[45] - A.S. Nursing provided 5.5 million hours of nursing services, expanding its user base in Israel[45] - Natali (China) expanded its business scope with insurance companies, adding high-end elderly care services, aging-friendly renovations, and health tourism[45] - Natali successfully acquired UK home care service companies Nobilis and Horizon, establishing a UK operational platform[45] - Natali acquired a 30% minority stake in subsidiary SHARAP, focusing on medical and emergency services in rural Israel[45] - QiLu Stem Cell optimized its stem cell service system and passed the blood station license renewal inspection[47] - QiLu Stem Cell organized a stem cell clinical application and regenerative medicine conference, enhancing brand influence[47] - QiLu Stem Cell conducted research on umbilical cord blood mononuclear cell composition analysis and umbilical plasma exosome effectiveness, achieving phased results[47] - Dendreon USA strengthened the product positioning of PROVENGE as a therapy for early-stage asymptomatic or mildly symptomatic mCRPC patients[49] - DanRui USA completed the optimization of its sales organization structure, enhancing sales service capabilities[50] - DanRui USA deepened its collaboration with Shoreline in 2023, successfully delivering the first GMP production batch and advancing NK cell production services[51] - DanRui USA evaluated over 200 projects since 2022, focusing on those with high potential and synergy for further research[51] - DanRui China enrolled 108 patients in the PROVENGE Phase III clinical trial, out of a planned total of 140 patients, as of June 2024[51] - DanRui China implemented strategic planning to establish a sustainable business model, leveraging PROVENGE as a key product[52] - New Health Hospital recorded over 207,000 outpatient visits and approximately 26,000 inpatient discharges in the first half of 2024[52] - DanRui's revenue for the first half of 2024 was RMB 3.251 billion, a 0.4% increase year-over-year[53] - DanRui's management expenses increased by 20.01% to RMB 686.07 million in the first half of 2024[53] - DanRui's financial expenses decreased by 47.87% to RMB -47.64 million due to increased deposit interest income[53] - DanRui's investment activities resulted in a net cash outflow of RMB 689.42 million, primarily due to the purchase of financial products[53] - Sanpower International Healthcare Group Ltd reported revenue of 738.03 million RMB and net profit of 37.10 million RMB[57] - Shiding Shengwu Biotechnology (Hong Kong) Trading Limited reported revenue of 776.40 million RMB and net profit of 75.24 million RMB[57] - Xuzhou New Health Geriatric Hospital Co., Ltd. achieved a net profit of 364.197 million yuan, a 27.13% increase compared to the previous year[65] - Shandong Qilu Stem Cell Engineering Co., Ltd. reported a net profit of 3,173.251 million yuan, a 9.53% decrease compared to the previous year[65] - Sanpower International Healthcare Group Co., Ltd. recorded a net profit of 370.

证券代码：600682 证券简称：南京新百 公告编号：临 2024-030 南京新街口百货商店股份有限公司 第十届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 监事会 1 表决结果：3 票同意，0 票反对，0 票弃权。 二、《关于控股子公司会计估计变更的议案》 监事会意见：本次公司控股子公司会计估计变更符合相关法律法规的规定和 公司实际业务经营情况，可以更客观、公允地反映公司的财务状况和经营成果， 不存在损害公司及全体股东，特别是中小股东利益的情形。公司监事会同意本次 会计估计变更。 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 南京新街口百货商店股份有限公司 南京新街口百货商店股份有限公司（以下简称公司）第十届监事会第二次 会议（以下简称会议）于 2024 年 8 月 29 日以通讯表决的方式召开。会议通知于 2024 年 8 月 19 日以电话或邮件的方式向全体监事发出，本次会议应参会监事 3 人，实际参会监事 3 人。本次会议的通知、召开以及参与表决监事人数均符合有 关法律、法规 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2024-029 南京新街口百货商店股份有限公司 第十届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）第十届董事会第十二次 会议（以下简称会议）于 2024 年 8 月 29 日以通讯表决的方式召开。会议通知于 2024 年 8 月 19 日以电话或邮件的方式向全体董事发出，本次会议应参会董事 11 人，实际参会董事 11 人。本次会议的通知、召开以及参与表决董事人数均符合 有关法律、法规、规则及《公司章程》的规定。会议审议并通过了如下议案： 一、《2024 年半年度报告及摘要》 详见同日披露于上海证券交易所网站（www.sse.com.cn）的公司《2024 年半 年度报告》及《2024 年半年度报告摘要》。 本次公司控股子公司徐州新健康老年病医院有限公司会计估计变更，将医疗 设备折旧年限由 5 年变更为 10 年。 本议案已经公司第十届董事会审计委员会审议通过。该议案无需提交股东大 会审议。 ...

证券代码：600682 证券简称：南京新百 公告编号：临2024-028 南京新街口百货商店股份有限公司 关于子公司会计估计变更的公告 重要内容提示： 一、会计估计变更概述 南京新街口百货商店股份有限公司（以下简称公司或本公司）于2024年8月29 日召开公司第十届董事会第十二次会议和第十届监事会第二次会议，审议通过了 《关于控股子公司会计估计变更的议案》。本次公司控股子公司徐州新健康老年 病医院有限公司（以下简称新健康医院）会计估计变更，将医疗设备折旧年限由 5年变更为10年，该会计估计变更无需提交股东大会审议。 二、具体情况及对公司的影响 （一）会计估计变更原因及内容 根据企业会计准则第28号、同行业公司实操惯例及公司子公司新健康医院的 医疗设备的实际使用情况，公司相关部门重新核定了新健康医院医疗设备的预计 使用年限。公司决定从2024年1月1日起调整新健康医院医疗设备折旧年限，具体 方案如下： | 资产类别 | 变更前 | | 变更后 | | | --- | --- | --- | --- | --- | | | 折旧年限（年） | 净残值率（%） | 折旧年限（年） | 净残值率（%） | | 机器设 ...

法律意见书 江苏泰和律师事务所 关于南京新街口百货商店股份有限公司 2023 年度差异化权益分派事项的 专项法律意见书 关于南京新街口百货商店股份有限公司 2023 年度差异化权益分派事项的 专项法律意见书 泰和律师事务所 法律意见书 江苏泰和律师事务所 关法律事项之目的而使用，非经本所事先书面许可，不得用于其他任何目的。 本所同意将本法律意见书作为南京新百本次差异化权益分派的必备法律文 件之一，随其他申请材料一起上报或公开披露，并依法对出具的法律意见书承担 相应的法律责任。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，对南 京新百 2023 年度利润分配所涉及的差异化权益分派事项所涉及的有关事实进行 了核查和验证，现发表法律意见如下： 一、本次差异化权益分派的原因 致：南京新街口百货商店股份有限公司 江苏泰和律师事务所（以下简称"本所"）接受南京新街口百货商店股份有限 公司(以下简称"南京新百"或"公司"的委托，根据《中华人民共和国公司法》(以 下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、《上 市公司股份回购规则》(以下简称"《回购规则》")、《上海证券交易 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2024-026 南京新街口百货商店股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.03 元（含税）。 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所上市公司自律 监管指引第 7 号—回购股份》等相关法律、行政法规、部门规章及其他规范性文件，公司回购 专用账户中的股份，不享有股东大会表决权、利润分配、公积金转增股本、认购新股和可转换 公司债券等权利。 3. 差异化分红送转方案： （1）本次利润分配以方案实施前的公司总股本 1,346,132,221 股扣除公司回购专户的股 份 7,000,000 股为基数，每股派发现金红利 0.03 元（含税），共计派发现金红利 40,173,966.63 元（含税）。本次 ...

一、本次股份被继续冻结基本情况 二、股东股份累计被冻结情况 证券代码：600682 证券简称：南京新百 公告编号：临 2024-025 南京新街口百货商店股份有限公司 关于控股股东部分股份被继续冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）于 2018 年 8 月 2 日、 2021 年 7 月 23 日分别披露了《南京新百关于控股股东股权被轮候冻结的公告》、 《南京新百关于控股股东部分股份被继续冻结的公告》（公告编号：临 2018-102、 2021-023），涉及控股股东三胞集团有限公司（以下简称三胞集团）所持公司 303,743,775 股被轮候冻结事项，冻结期限 3 年。 2024 年 7 月 8 日，公司收到中国证券登记结算有限责任公司上海分公司《股 权司法冻结及司法划转通知》[2024 司冻 0704-1 号]、《江苏省南京市中级人民 法院协助执行通知书》[（2020）苏 01 执 192 号]。控股股东三胞集团所持公司 303,743,775 股股份被继 ...

关于对南京新街口百货商店股份有限公 2023年度报告的信息披露监管工作函有关问 致:上海证券交易所上市公司 接到南京新街口百货商店股份有限公司（以下简称"南京新百"或"公司"）转来的《关于南京 新街口百货商店股份有限公司2023年度报告的信息披露监管工作函》（上证公函【2024】0622号，以 下简称工作函），我们对工作函中相关问题进行了认真核查,核查情况如下: 一、关于公司经营情况 2 、年 报 披 露 ， 公 司 境 外 子 公 司 Sanpower International Healthcare Group Ltd (以下简称"三胞国际")2023 年度净利润 3386 万元,同比下降 60.59%;世鼎生物 技术(香港)有限公司(以下简称"世鼎香港")2023年度净利润分别为 1.27 亿元，同比 下降 52.03%。上述公司业绩连续两年大幅下滑,合计商誉总额 30.43 亿元,本期仅计提 8355.83 万元。请公司: (1)结合上述公司最近三年所处行业发展趋势、产品和竞争力、 销售价格与成本变化情况等,说明业绩持续大幅下滑的原因,是否存在进一步下滑的风险; (2)补充披露上述公司主要资产情况,包 ...